Best practices for treating unresectable, locally advanced bladder cancer continue to evolve. Read my thoughts on tailoring treatment based on specific patient and disease characteristics in this setting.
The evolution of immune checkpoint inhibitors for advanced bladder cancer may eventually replace chemotherapy. Read my thoughts on these new agents and how I use them in the clinic.
Patients with bladder cancer benefit most from a multidisciplinary approach tailored to their disease course. Read my thoughts on when and how urologists and oncologists should consider multidisciplinary patient management.
Immune checkpoint inhibitors (ICIs) have expanded treatment options for patients who cannot tolerate chemotherapy. Read my thoughts on using ICIs in clinical practice, as well as some of the most promising salvage strategies for patients who progress on them.
Are you aware of the recent FDA alert limiting first-line use of immune checkpoint inhibitors in patients with urothelial carcinoma? In this commentary, I explore the reasons for and the ramifications of this change.
Are you aware of promising new options in clinical trials for your patients with bladder cancer who cannot receive cisplatin? Read my thoughts on the potential roles of neoadjuvant pembrolizumab and atezolizumab.
This Interactive Decision Support Tool will let you compare your choice of therapy for patients with advanced bladder cancer with expert recommendations from Matthew Galsky, MD; Matthew I. Milowsky, MD; Daniel P. Petrylak, MD; Elizabeth R. Plimack, MD, MS; and Jonathan E. Rosenberg, MD.
In this virtual presentation, Elizabeth R. Plimack, MD, MS discusses the clinical rationale and data on the use of immune checkpoint inhibitors for patients with advanced bladder cancer. Afterwards, download the slides and use the treatment decision tool for your practice.
In this downloadable slideset, Elizabeth R. Plimack, MD, MS, discusses the current clinical rationale and most recent data on immune checkpoint inhibitors for patients with advanced bladder cancer. Click here to use our online tool to see how to select optimal therapy for your patients.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.